These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 16507397)

  • 1. Study of COX-2, Ki67, and p53 expression to predict effectiveness of 5-flurouracil, epirubicin and cyclophosphamide with celecoxib treatment in breast cancer patients.
    Chow LW; Loo WT; Wai CC; Lui EL; Zhu L; Toi M
    Biomed Pharmacother; 2005 Oct; 59 Suppl 2():S298-301. PubMed ID: 16507397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclooxygenase-2 inhibition does not improve the reduction in ductal carcinoma in situ proliferation with aromatase inhibitor therapy: results of the ERISAC randomized placebo-controlled trial.
    Bundred NJ; Cramer A; Morris J; Renshaw L; Cheung KL; Flint P; Johnson R; Young O; Landberg G; Grassby S; Turner L; Baildam A; Barr L; Dixon JM
    Clin Cancer Res; 2010 Mar; 16(5):1605-12. PubMed ID: 20179229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.
    Bottini A; Berruti A; Bersiga A; Brizzi MP; Brunelli A; Gorzegno G; DiMarco B; Aguggini S; Bolsi G; Cirillo F; Filippini L; Betri E; Bertoli G; Alquati P; Dogliotti L
    Clin Cancer Res; 2000 Jul; 6(7):2751-8. PubMed ID: 10914720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Celecoxib modulates the expression of cyclooxygenase-2, ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot study.
    Ferrandina G; Ranelletti FO; Legge F; Lauriola L; Salutari V; Gessi M; Testa AC; Werner U; Navarra P; Tringali G; Battaglia A; Scambia G
    Clin Cancer Res; 2003 Oct; 9(12):4324-31. PubMed ID: 14555502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic effect of celecoxib on 5-fluorouracil-induced apoptosis in hepatocellular carcinoma patients.
    Bassiouny AR; Zaky A; Neenaa HM
    Ann Hepatol; 2010; 9(4):410-8. PubMed ID: 21057160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.
    Edelman MJ; Watson D; Wang X; Morrison C; Kratzke RA; Jewell S; Hodgson L; Mauer AM; Gajra A; Masters GA; Bedor M; Vokes EE; Green MJ
    J Clin Oncol; 2008 Feb; 26(6):848-55. PubMed ID: 18281656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparison of epirubicin and cyclophosphamide in 2-dose levels and classical CMF protocol in node-positive breast cancer. An adjuvant Phase III trial].
    Ost E; Illiger HJ
    Strahlenther Onkol; 2002 Jan; 178(1):54-5. PubMed ID: 11977396
    [No Abstract]   [Full Text] [Related]  

  • 8. An EORTC phase I study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-fu (CEF-infu) as primary treatment of large operable or locally advanced/inflammatory breast cancer.
    Bonnefoi H; Biganzoli L; Cufer T; Mauriac L; Hamilton A; Schaefer P; Piccart M
    Breast Cancer Res Treat; 2001 Nov; 70(1):55-63. PubMed ID: 11768362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increases in circulating VEGF levels during COX-2 inhibitor treatment in breast cancer patients.
    Ueno T; Chow LW; Toi M
    Biomed Pharmacother; 2006 Jul; 60(6):277-9. PubMed ID: 16806797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-surgical study of the biological effects of the selective cyclo-oxygenase-2 inhibitor celecoxib in patients with primary breast cancer.
    Martin LA; Davies GL; Weigel MT; Betambeau N; Hills MJ; Salter J; Walsh G; A'Hern R; Dowsett M
    Breast Cancer Res Treat; 2010 Oct; 123(3):829-36. PubMed ID: 20697803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial.
    Bartlett JM; Munro A; Cameron DA; Thomas J; Prescott R; Twelves CJ
    J Clin Oncol; 2008 Nov; 26(31):5027-35. PubMed ID: 18768436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor properties of taxol in combination with cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on ovarian tumor growth in vivo.
    Li W; Zhai L; Tang Y; Cai J; Liu M; Zhang J
    Oncol Res; 2012; 20(2-3):49-59. PubMed ID: 23193911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer.
    Brandão RD; Veeck J; Van de Vijver KK; Lindsey P; de Vries B; van Elssen CH; Blok MJ; Keymeulen K; Ayoubi T; Smeets HJ; Tjan-Heijnen VC; Hupperets PS
    Breast Cancer Res; 2013 Apr; 15(2):R29. PubMed ID: 23566419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of cell cycle regulatory proteins in breast carcinomas before and after preoperative chemotherapy.
    Pohl G; Rudas M; Taucher S; Stranzl T; Steger GG; Jakesz R; Pirker R; Filipits M
    Breast Cancer Res Treat; 2003 Mar; 78(1):97-103. PubMed ID: 12611462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Celecoxib inhibits tumor growth and angiogenesis in an orthotopic implantation tumor model of human colon cancer.
    Wang L; Chen W; Xie X; He Y; Bai X
    Exp Oncol; 2008 Mar; 30(1):42-51. PubMed ID: 18438340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclooxygenase-2 inhibition: effects on tumour growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancer.
    Barnes NL; Warnberg F; Farnie G; White D; Jiang W; Anderson E; Bundred NJ
    Br J Cancer; 2007 Feb; 96(4):575-82. PubMed ID: 17285134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acceptable cardiac safety profile of neoadjuvant 5-fluorouracil, epirubicin, cyclophosphamide and celecoxib (FEC-C) for breast cancer: a subanalysis of biomarkers for cardiac injury.
    Chow LW; Loo WT; Yip AY; Ng EL
    Int J Biol Markers; 2013 Apr; 28(1):E92-9. PubMed ID: 23592005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment.
    Generali D; Buffa FM; Deb S; Cummings M; Reid LE; Taylor M; Andreis D; Allevi G; Ferrero G; Byrne D; Martinotti M; Bottini A; Harris AL; Lakhani SR; Fox SB
    Br J Cancer; 2014 Jul; 111(1):46-54. PubMed ID: 24874483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant therapy with celecoxib to women with early stage breast cancer.
    Tfayli A; Yang J; Kojouri K; Kesserwan C; Jafari M; Ozer H
    Neoplasma; 2008; 55(2):122-6. PubMed ID: 18237249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial.
    Hamy AS; Tury S; Wang X; Gao J; Pierga JY; Giacchetti S; Brain E; Pistilli B; Marty M; Espié M; Benchimol G; Laas E; Laé M; Asselain B; Aouchiche B; Edelman M; Reyal F
    J Clin Oncol; 2019 Mar; 37(8):624-635. PubMed ID: 30702971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.